^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    iparomlimab (QL1604)

    i
    Other names: QL1604, PSB103, QL-1604, QL 1604
    Company:
    Qilu Pharma
    Drug class:
    PD1 inhibitor
    Related drugs:
    7d
    The exploration of iparomlimab and tuvonralimab combined with de-escalated chemotherapy as an innovative neoadjuvant treatment strategy for locally advanced cervical cancer: a case report from the NICE-CC trial. (PubMed, Front Immunol)
    In conclusion, this case highlights the potential of one cycle of neoadjuvant dual immunotherapy combined with standard chemotherapy, followed by two additional cycles of dual immunotherapy, for the treatment of LACC. This innovative treatment regimen warrants further investigation in the ongoing NICE-CC trial.
    Journal
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 negative
    |
    Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    13d
    SFRT+Sequential Hypofractionated/Conventional Fractionated RT+Iparomlimab and Tuvonralimab for Relapsed/Refractory Solid Tumors (clinicaltrials.gov)
    P2, N=30, Recruiting, Second Affiliated Hospital of Nanchang University | Not yet recruiting --> Recruiting
    Enrollment open • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    25d
    Single-Arm, Phase II Clinical Study of Ipalolimab and Tovorelimab in Combination with Regorafenib and Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (G/GEJ) Adenocarcinoma (ChiCTR2600120217)
    P2, N=35, Jiangsu Province Hospital (The First Affiliated Hospital with Nanjing Medical University); Jiangsu Province Hospital (The First Affiliated Hospital wi
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    capecitabine • Stivarga (regorafenib) • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur) • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    26d
    A randomized, open-label, multicenter clinical study comparing the combination of epalorlimovalizumab and bevacizumab with TAS-102 versus bevacizumab combined with TAS-102 in the second-line treatment of advanced colorectal cancer (ChiCTR2500106797)
    P4, N=84, Henan Cancer Hospital; Henan Cancer Hospital | Initiation date: Aug 2025 --> Apr 2026
    Trial initiation date
    |
    CXCL10 (Chemokine (C-X-C motif) ligand 10) • SPP1 (Secreted Phosphoprotein 1) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • GBP5 (Guanylate Binding Protein 5) • STAT1 (Signal Transducer And Activator Of Transcription 1) • APOE (Apolipoprotein E) • GBP1 (Guanylate Binding Protein 1) • TAP1 (Transporter 1) • GBP4 (Guanylate Binding Protein 4) • MX1 (MX Dynamin Like GTPase 1) • SDC2 (Syndecan 2)
    |
    Avastin (bevacizumab) • Lonsurf (trifluridine/tipiracil) • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    1m
    Iparomlimab Plus Tovorilimab Combined With Bevacizumab and Chemotherapy as First-Line Treatment for Advanced Mesothelioma (clinicaltrials.gov)
    P2, N=37, Not yet recruiting, Fudan University
    New P2 trial
    |
    Avastin (bevacizumab) • cisplatin • carboplatin • pemetrexed • iparomlimab (QL1604)
    1m
    A Prospective, Single-Arm, Exploratory Study of the Safety and Efficacy of Neoadjuvant Treatment With QL1706, an Anti-PD-1/Anti-CTLA-4 Bispecific Antibody, in Resectable Stage IB and IIA Hepatocellular Carcinoma With High Recurrence Risk (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P2 trial
    |
    Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    2ms
    Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing (clinicaltrials.gov)
    P2, N=39, Recruiting, Peking Union Medical College | Trial primary completion date: Jul 2026 --> Jul 2028
    Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    carboplatin • Perjeta (pertuzumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • Lenvima (lenvatinib) • AiRuiKa (camrelizumab) • AiTan (rivoceranib) • Piqray (alpelisib) • Irene (pyrotinib) • albumin-bound paclitaxel • abiraterone acetate • fulvestrant • Aidixi (disitamab vedotin) • exemestane • Padcev (enfortumab vedotin-ejfv) • bicalutamide • Kaitanni (cadonilimab) • goserelin acetate • Qibeian (iparomlimab/tuvonralimab) • Yidafan (ivonescimab) • iparomlimab (QL1604) • leuprolide acetate for depot suspension • Entyvio (vedolizumab)
    2ms
    A Clinical Study of Iparomlimab and Tuvonralimab Combined With Fruquintinib and Heterogeneous Radiotherapy Versus Fruquintinib as Third-Line and Subsequent-Line Treatment for Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, Huazhong University of Science and Technology
    New P2 trial
    |
    Fruzaqla (fruquintinib) • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    2ms
    A Clinical Study of Iparomlimab and Tuvonralimab Combined With SOX Following Heterogeneous Radiotherapy as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Gastric or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov)
    P4, N=55, Not yet recruiting, Huazhong University of Science and Technology
    New P4 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    oxaliplatin • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    2ms
    Clinical Study on the Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Nab-Paclitaxel in Neoadjuvant Therapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=26, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P2 trial
    |
    albumin-bound paclitaxel • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    2ms
    Neoadjuvant Therapy With Iparomlimab and Tuvonralimab, Lenvatinib and Chemotherapy in Resectable ESCC (clinicaltrials.gov)
    P2, N=33, Not yet recruiting, Changhai Hospital
    New P2 trial
    |
    cisplatin • carboplatin • Lenvima (lenvatinib) • albumin-bound paclitaxel • epacadostat (INCB024360) • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    3ms
    Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCC (clinicaltrials.gov)
    P2, N=27, Recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University
    New P2 trial • Tumor mutational burden
    |
    EGFR (Epidermal growth factor receptor)
    |
    cisplatin • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)